Table 2:
Prevalence of symptoms at the initial screening according to transglutaminase autoantibody (TGA) status
| TGA | |||
|---|---|---|---|
| Symptoms | RBA + n=187 n (%) |
NegativeA n=9,731 n ( %) |
P-value |
| Weight Loss | 6 (3.2%) | 334 (3.4%) | 0.87 |
| Vomiting | 12 (6.4%) | 347 (3.6%) | 0.04 |
| Poor Growth | 10 (5.4%) | 455 (4.7%) | 0.66 |
| Stomach Aches | 50 (26.7%) | 2142 (22.0%) | 0.12 |
| Diarrhea | 11 (5.9%) | 454 (4.7%) | 0.44 |
| Constipation | 22 (11.8%) | 1158 (11.9%) | 0.95 |
| Any of the above | 60 (32.1%) | 2,970 (30.5%) | 0.65 |
| Two or more symptoms | 35 (18.7%) | 1329 (13.7%) | 0.05 |
(TGA, tissue transglutaminase; RBA, radiobinding assay)
A
This analysis excluded the 55 ECL positive only participants.